Insulet Corporation (PODD) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Insulet Corporation (PODD)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

267.30

-0.69 (-0.26%)

At close: Jan 14, 2025, 3:59 PM

266.50

-0.30%

Pre-market Jan 15, 2025, 05:23 AM EST

undefined% (undefined)

Bid	258
Market Cap	18.75B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	5.87
PE Ratio (ttm)	45.54
Forward PE	n/a
Analyst	Buy

Ask	280
Volume	348,056
Avg. Volume (20D)	553,562
Open	268.90
Previous Close	267.99
Day's Range	262.49 - 271.13
52-Week Range	160.19 - 279.77
Beta	undefined

About PODD

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly i...

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date May 15, 2007

Employees 3,000

Stock Exchange NASDAQ

Ticker Symbol PODD

Website https://www.insulet.com

Analyst Forecast

According to 16 analyst ratings, the average rating for PODD stock is "Buy." The 12-month stock price forecast is $277.5, which is an increase of 3.82% from the latest price.

Buy 81.25%

Hold 12.50%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Insulet Corporation is scheduled to release its earnings on Feb 20, 2025, after market closes.
Analysts project revenue of $582.02M, reflecting a 14.17% YoY growth and earnings per share of 1.02, making a -27.14% decrease YoY.

Why Price Moved

1 week ago · Source

+3.68%

Insulet shares are trading higher after TD Cowen r... Unlock content with Pro Subscription

3 weeks ago · Source

+3.9%

Insulet shares are trading higher amid strength in diabetes-related stocks following weight loss data from Novo Nordisk.

News

1 day ago · zacks.com

PODD Stock Gains From the Launch of Omnipod 5 in Five Countries in EU

Insulet announces the launch of Omnipod 5 in five more countries in Europe, Italy, Denmark, Finland, Norway and Sweden.

1 day ago · businesswire.com

Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced t...

5 days ago · businesswire.com

Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

2 weeks ago · zacks.com

GEHC vs. PODD: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical - Products sector have probably already heard of GE HealthCare Technologies (GEHC) and Insulet (PODD). But which of these two companies is the best opti...

2 weeks ago · fxempire.com

Heavy Interest in Insulet's Insulin Delivery Device

Sales are surging for Insulet Corporation (PODD).

1 month ago · zacks.com

Why Insulet (PODD) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

1 month ago · zacks.com

RMD or PODD: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Products stocks are likely familiar with ResMed (RMD) and Insulet (PODD). But which of these two companies is the best option for those looking for undervalued stocks...

1 month ago · zacks.com

Should You Continue to Retain Insulet Stock in Your Portfolio Now?

PODD stock stays on investors' radar owing to its solid progress with Omnipod 5 and robust potential in the diabetes market.

1 month ago · reuters.com

Insulet wins $452 mln US verdict against EOFlow in insulin pump secrets case

Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade secrets related to insulin pumps, according to a verdict made public in Massac...

1 month ago · businesswire.com

Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court

1 month ago · zacks.com

Here's Why Insulet (PODD) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

1 month ago · zacks.com

PODD Stock to Gain From Launch of Omnipod 5 With Abbott's CGM in US

Insulet's Omnipod 5 System is now compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the United States.

1 month ago · seekingalpha.com

Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines

Insulet's stock has surged over 50% in six months due to strong Q3 earnings and expanded market potential with Omnipod 5's approval for Type 2 diabetes. Despite impressive growth, high market expectat...

1 month ago · businesswire.com

Insulet Announces Omnipod® 5 System is Now Compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the U.S.

2 months ago · businesswire.com

Insulet to Present at Upcoming Investor Conferences

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management ...

2 months ago · zacks.com

Buy Profitable S&P 500 Stocks as the Index Tops 6000: NVIDIA & 2 More

NVIDIA, Insulet and Howmet Aerospace have been selected as the top picks with a high net income ratio.

2 months ago · zacks.com

Why Insulet (PODD) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

2 months ago · zacks.com

PODD Stock Gains on Q3 Earnings and Revenue Beat, '24 Sales View Up

Insulet's third-quarter performance benefits from the continued high demand for Omnipod 5.

2 months ago · youtube.com

Insulet CEO on earnings, GLP-1 and election impact

Jim Hollingshead, Insulet CEO, joins 'Closing Bell: Overtime' to discuss the Insulet earnings, Apple blood sugar testing app and more.

2 months ago · forbes.com

Buy, Sell, Or Hold Insulet (PODD) Stock?

Insulet stock (NASDAQ: PODD) surged nearly 10% on Friday, November 8, after the company posted an upbeat Q3 and raised its sales outlook. It reported sales of $544 million and adjusted earnings of $0....

Load More News